In this study, 2-iodo substituted 1-methylpiperidin-2-yl benzamide derivatives were synthesized and evaluated as candidate SPECT imaging agents for glycine transporter 1 (GlyT1). In JAR cells, which predominantly express GlyT1, 2-iodo N-[(S)-{(S)-1-methylpiperidin-2-yl}(phenyl)methyl] 3trifluoromethyl-benzamide (5) showed excellent inhibitory activity of [ 3 H]glycine uptake (IC 50 = 2.4 nM). Saturation assay in rat cortical membranes revealed that [ 125 I]5 had a single high affinity binding site with a Kd of 1.54 nM and a Bmax of 3.40 pmol/mg protein. In vitro autoradiography demonstrated that [ 125 I]5 showed consistent accumulation with GlyT1 expression. The in vitro binding was greatly inhibited by GlyT1 inhibitors but not by other site ligands, which suggested the high specific binding of [ 125 I]5 with GlyT1. In the biodistribution and ex vivo autoradiography studies using mice, [ 125 I]5 showed high blood-brain barrier permeability (1.68-2.17% dose/g at 15-60 min) and similar regional brain distribution pattern with in vitro results. In addition, pre-treatment of GlyT1 ligands resulted in significant decrease of [ 125 I]5 binding in the GlyT1-rich regions.
Introduction
Glycine has dual physiological functions as an inhibitory neurotransmitter for strychnine-sensitive glycine receptors (GlyRs) and as a co-agonist for NMDA receptors which play key roles in excitatory glutamatergic transmission. 1 Glycine transporters (GlyTs) modulate these neurotransmissions by controlling glycine concentration in the synaptic cleft of glial and neuronal cells. GlyTs are classified into two sodium/chloride dependent transporters, GlyT1 and GlyT2. 2 It is considered that GlyT2 participate in inhibitory glycinergic neurotransmission, because they are mainly expressed by glycinergic neurons in the caudal regions, such as the spinal cord and brain stem. In contrast, GlyT1 are widely expressed in many brain regions, such as the forebrain and caudal regions. Therefore GlyT1 are thought to regulate the glycine concentration in both excitatory NMDA receptors and inhibitory GlyRs. 3 Dysfunction of the NMDA receptor is thought to be involved in various disorders such as schizophrenia, stroke, Parkinson's Disease, and Alzheimer's Disease. 4 Alterations in the ambient glycine concentration are known to have modulatory effects on the NMDAR. 3 Specifically, pharmacological modulation of glycine-mediated neurotransmission by recently developed various GlyT-1 inhibitors ( Figure 1 ) revealed beneficial effect to the negative and cognitive symptoms of schizophrenia. [5] [6] [7] First generation GlyT1 inhibitors are glycine derivatives, such as ALX5407 and Org24461 with high inhibitory potency. 8 Unfortunately, none of these compounds are expected to be promising drug candidates because of their safety profiles and pharmacokinetics. 9 More recently, second generation non-amino acid type series of compounds have been developed as potent GlyT1 inhibitors. Some of them showed positive results for clinical use in the treatment of schizophrenia. 6, 9 In addition, recent reports suggested that GlyT1 inhibitors could be also applied for various disorders such as depression, anxiety, seizures, and neuropathic pain by modulating NMDA receptor or inhibitory GlyRs. 10, 11 However, the existence of a correlation between the progress of such diseases and the change of GlyT1 expression and activity remains to be solved.
Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are the efficient imaging methods for noninvasive visualization of target proteins. Development of novel imaging probes for GlyT1 is, thus, considered useful for obtaining information about such diseases and occupancy of GlyT1 inhibitors in vivo. Most recently, several non-amino acid type 11 C or 18 F radiotracers were developed as PET potential ligands for GlyT1 as shown in Figure 2 . The [ 18 F]MK-6577 and [ 11 C]GSK931145 had been demonstrated to be promising GlyT1 imaging agents because of good blood brain barrier permeability, consistent accumulation with GlyT1 expression, and displacement to homogenous level by GlyT1 ligands in the pig or rhesus monkey brain in vivo. 12, 13 Furthermore [ 11 C]GSK931145 was applied for human PET studies which resulted in similar binding property with non-human brain.
However this tracer showed unsatisfactory signal-to-noise ratio and reproducibility because of significantly lower plasma free fraction and K 1 value in humans. 14 On the other hand, SSR504734 and its derivatives have been reported that selective and competitive inhibitors of GlyT-1 recently. 15, 16 Since these compounds have molecular of approximately 400 and possess moderate lipophilicity, they may be useful lead compounds for the development of imaging agents. In a most recent report, SSR504734-related radioligands such as [ 11 C]SA1 showed high brain uptake and consistent accumulation with GlyT1 distribution in the monkey brain; however, the total volume of distribution (Vt) was not significantly decreased by GlyT1 ligands. 17 The clinical usefulness of recently developed PET ligands remains to be investigated. The need to develop new imaging agents with optimal in vivo binding property still arises. In addition, there is still no SPECT imaging agent for GlyT1 reported. Accordingly, this study attempted to develop new SPECT imaging agents; wherein, a radioiodine atom was introduced into the 2-position of SSR504734 derivatives. Hence, we present the synthesis of new GlyT1 ligands, 125 I labeling, and preliminary in vitro and in vivo binding characterization in rodents.
Results and discussion

Chemistry
The synthetic scheme of N-Me-SSR504734 (4) and 2-iodo-substituted SSR504734 derivatives (3 and 5) were presented in scheme 1.
(S)-{(S)-1-allylpiperidin-2-yl} (phenyl) methanamine (1) was prepared according to the literature. 18 General coupling reaction of 1 with 3-trifluoromethyl-2-iodobenzoic acid resulted in 71% yield of amide 2. Subsequent Pd(0) catalyzed deprotection of allyl group provided compound 3 (88% yield).
Finally, reductive amination of SSR504734 18 and 3 yielded 94% of N-Me-SSR504734 (4) and 95% of compound 5.
[ 3 H]glycine uptake assay
Assays for the inhibitory activities of GlyT1 were performed based on the reported method utilizing [ 3 H]glycine uptake into JAR cells. 19 The inhibitory activity of each compound was expressed as IC 50 values as shown in Table 1 .
Whereas SSR504734 showed modest inhibitory activity (IC 50 = 80.1 nM), its N-methyl derivative 4 showed 11-fold higher activity (IC 50 = 7.51 nM). These results are consistent with the literature; wherein, GlyT1 expressed in CHO cells resulted in the respective IC 50 of 314 nM and 2.5 nM for SSR504734 and 4. 16 Introduction of an iodine atom into the X-position of SSR504734 resulted in the improvement of inhibitory activity (3, 43.0 nM). Notably, compound 5 exhibited excellent inhibitory activity (IC 50 = 2.4 nM), which was 18-fold and triplicate higher than 3 and 4, respectively. These results indicate the importance of the methyl group in R-position for GlyT1 inhibition and the iodine atom is preferred over the chloride atom in the X-position to manifest strong inhibitory activity. On the other hand, a first generation GlyT1 inhibitor, ALX5407, showed 6-fold higher inhibitory activity than 5 (IC 50 = 0.39 nM). This extraordinary potent inhibitory activity of ALX5407 correlates with the result of a previous report (IC 50 = 0.3 nM). 20 
Radiochemistry
According to the [ 3 H]glycine uptake assay, this study investigated the potential of radio-iodinated 5 as a candidate SPECT imaging agent for GlyT1. 
In vitro binding characterization
In order to investigate the binding property of [ 125 I]5, saturation assays in the rat cortical brain homogenates were carried out. The saturation curve and scatchard plot are shown in Figure 3 . The binding of [ 125 I]5 was calculated to be a well-fitted one binding site model (R 2 =0.985) with high affinity (Kd= 1.58 ± 0.34 nM). The Bmax value was estimated to be 3.40 ± 0.18 pmol/mg protein which is consistent with the results of other radioligands for GlyT1. 21, 22 To characterize in vitro regional brain distributions of [ 125 I]5, autoradiography experiments using the rat brain sections were performed. As shown in the autoradiogram in Figure 4 , [ 125 I]5 showed high accumulation in the corpus callosum, thalamus, midbrain, medullary, and cerebellar white matter. On the other hand, low uptake of [ 125 I]5 was observed in the cerebral cortex, hippocampus, striatum, and cerebellar gray matter ( Figure 4A ). It should be noted that the accumulation pattern of [ 125 I]5 was quite similar to the distribution of GlyT1 immunoreactivity in the rat brain. 23 Nonspecific binding was determined in the presence of corresponding nonradioactive 5 (10 M), which resulted in a significant reduction of radioactivity accumulation in the whole brain compared with total binding. Additionally, regional differences in the [ 125 I]5
binding disappeared in the brain regions ( Figures inhibitory activity. 16 While 1 mM of glycine had almost no effect on the [ 125 I]5
binding, the increase to 10 mM caused reduction of accumulated radioactivity in all brain regions. These results suggest that compound 5 is a competitive inhibitor to the glycine binding site of GlyT1 and the binding affinity of glycine to the [ 125 I]5 binding site is much lower than the GlyT1 inhibitors. This binding property is similar to 4 (N-Me-SSR504734) as reported previously. 16 ORG25543
and L-701,324 did not affect the [ 125 I]5 binding in all brain regions.
The results of in vitro experiments indicate that [ 125 I]5 selectively binds to
GlyT1. Therefore, our study attempted to perform in vivo studies in order to validate the effectiveness of radio-iodinated 5 as a SPECT imaging agent for GlyT1.
In vivo studies
The biodistribution studies of [ 125 I]5 were carried out using normal mice and the results are shown in Table 3 . High pulmonary uptake of [ 125 I]5 was observed at all points in time (9.34−17.19%dose/g), which could be attributed to the piperidine moiety of this tracer. Initial brain uptake of [ 125 I]5 was 0.51% dose/g at 0.5 min after intravenous injection. Radioactivity of [ 125 I]5 in the brain tissue increased with time and peaked to 2.42% dose/g at 30 min, suggesting the good blood-brain barrier permeability of [ 125 I]5. Although brain uptake of [ 125 I]5
gradually decreased after 30 min, brain to blood ratios remained at the same level at 60 min (2.46 and 2.32% dose/g at 30 and 60 min, respectively). It is suggested that radiotracers with moderate lipophilicity (logD 7.4 values; 2.0-3.5) show optimal passive brain entry under in vivo condition. 25 Next, the specificity of regional brain binding of [ 125 I]5 toward GlyT1 was studied by blocking studies using non-radioactive 5, compound 4, SSR504734, and ALX5407 (2 mg/kg, intravenously), which were administered 15 min prior to injection of the radioligand. Because brain/blood ratio of [ 125 I]5 peaked at 30 and 60 min as shown in Table 3 , regional brain distribution studies were conducted at 30 and 60 min after the radiotracer injection. The results of in vivo blocking studies are shown in Figure 5 . Pre-injection of non-radioactive 5 resulted in which the reason could be due to the much lower inhibitory activity (Table 1 ) and binding affinity 16 for GlyT1 of SSR504734 than its N-methyl analogs, compound 4 and 5. Pretreatment with ALX5407 showed almost no effect to the regional brain uptake of [ 125 I]5 at 30 min. On the other hand, the brain uptake of [ 125 I]5 was decreased at 60 min; however, the reduction was not significant in most regions.
The slow and weak inhibitory effects of ALX5407 for [ 125 I]5 binding agree with in vitro results (Table 2) .
To investigate further in vivo binding property of [ 125 I]5 to GlyT1, we performed ex vivo autoradiography studies. Mice were injected intravenously with [ 125 I]5 and sacrificed 60 min after administration. As shown in Figure 6 , a high uptake of [ 125 I]5 was clearly visualized in the GlyT1-rich regions (thalamus, midbrain, cerebellum, and medullary). On the other hand, the accumulation was low in the GlyT1-poor regions (cerebral cortex, hippocampus and striatum). The low radioactivity of [ 125 I]5 in the corpus callosum was inconsistent with that shown in the in vitro autoradiography studies. The in vivo results might be due to the influence of regional blood flow in the brain. It is well known that blood flow in the white matter, such as the corpus callosum was lower than that of other brain regions. 27, 28 To further confirm the in vivo specificity of [ 125 I]5 for GlyT1, blocking studies were performed in which non-radioactive 5 or compound 4 (2 mg/kg body weight) was given as pretreatment before [ 125 I]5 injection. As shown in the autoradiogram images in Figures 6B and 6C Since the accumulation of [ 125 I]5 was dependent on GlyT1 expression and specific binding to GlyT1, this tracer is expected to be a promising SPECT probe for targeting GlyT1 in the living brain. Additionally, the N-methyl group of 5
could be labeled with carbon-11; therefore, compound 5 could be employed as a PET ligand. Further in vivo imaging studies of radio-labeled 5 are necessary to clarify the potential of this compound as a clinical useful imaging probe for GlyT1.
Conclusion
In this study, [ 125 I]5 was developed as a candidate SPECT ligand for GlyT1.
Compound 5 was discovered to possess potent GlyT1 inhibitory activity. In addition, [ 125 I]5 showed consistent binding with GlyT1 expression in the rodent brain and the accumulated radioactivity was significantly decreased by GlyT1 inhibitors in the GlyT1-rich regions both in vitro and in vivo. Altogether, the radio-iodinated 5 could be a promising SPECT probe for neuroimaging of central GlyT1.
Experimental
General information
All reagents were commercially available products and were used without further purification unless otherwise indicated. 1 The experiments with animals were conducted in accordance with our institutional guidelines and were approved by Nagasaki University Animal Care Committee. All animals were supplied by Tagawa Experimental Animal Laboratory (Nagasaki, Japan). To the stirred solution of compound 2 (172 mg, 0.33 mmol) in CH 2 Cl 2 (5 mL), The culture medium was removed from the 6-well plates and the JAR cells were incubated with 1.0 mL of TB1A buffer (120 mM NaCl, 2 mM KCl, 1 mM 
In vitro saturation assays
The in vitro saturation assays of [ 125 I]5 to rat cortical membrane homogenates were performed according to the method in the literature. 21 In brief, well washed membranes (25 g protein) were incubated with [ 125 I]5 (0.1-20 nM)
in 250 l of TB1 buffer (120 mM NaCl, 2 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, pH 7.5) for 60 min at room temperature. Non-specific binding was defined by the addition of unlabeled 5 at 10 M. Bound ligands were collected by rapid filtration using a Brandel cell harvester onto glass fiber filter (GF/B). The filters were washed rapidly three times with 2.5 mL of ice-cold assay buffer. The radioactivity of filters was measured by automated gamma counter.
In vitro autoradiography
In vitro autoradiogaphy studies were carried out according to the previous reports. 31 The brain sagittal sections (20 m) were pre-incubated for 20 min at 25 The radioactivities in these regions were expressed as photostimulated luminescence (PSL) values on ROI-background PSL value per square millimeter.
The specific binding was determined as the difference between total binding and binding in the presence of the corresponding nonradioactive 5 (10 M). Selectivity studies were performed as similar procedure in the presence of several drugs (10 M) except for glycine (1 mM or 10 mM).
In vivo experiments
The [ 125 I]5 (0.1 mL, ca. 11.1 kBq for whole body distribution studies, ca. 33.3 kBq for regional brain distribution studies) was injected intravenously via the tail vein into ddY mice (male, 6W, 30-35 g) . At the designated time intervals, the mice were killed and the organs were dissected. The brain was further divided into the cerebral cortex, hippocampus, and cerebellum.
The tissues were then weighed and the radioactivity was measured by presented in Figure 4 were statistically analyzed by Mann-Whitney U-test. In vivo experiments and ex vivo autoradiography of [ 125 I]5 described in Figure 5 and 
